bladder cancer

Antiangiogenesis Plus Chemotherapy Pursued in Advanced Bladder Cancer

Two separate phase II studies lend support to the concept of antiangiogenesis in advanced bladder cancer. The combination of an antiangiogenic agent and chemotherapy may fulfill an unmet need in this disease, the studies suggest. Both studies were presented at the 2015 Genitourinary Cancers...

Bladder Cancer

Adjuvant Chemotherapy and Overall Survival in Muscle-Invasive Bladder Cancer: Still Climbing the Mountain

Muscle-invasive bladder cancer can be a lethal disease despite curative intent local therapy, with 5-year survival that can be as low as 30% based on the extent of T status and/or lymph node involvement. The use of neoadjuvant chemotherapy with MVAC (methotrexate, vinblastine, doxorubicin, and...

bladder cancer

No Overall Survival Difference for Immediate vs Deferred Chemotherapy After Radical Cystectomy in Muscle-Invasive Bladder Cancer

In the European Organisation for Research and Treatment of Cancer (EORTC) 30994 trial, a phase III intergroup study reported in The Lancet Oncology,1 Cora N. Sternberg, MD, FACP, Chief of Medical Oncology at San Camillo and Forlanini Hospitals, Rome, and colleagues found no overall survival...

Bladder Cancer

Immunotherapy Marches On, Making Headway in Advanced Urothelial Bladder Cancer

Two immunotherapy agents show promise in preliminary studies of advanced urothelial bladder cancer: the anti–PD-1 (programmed cell death protein 1) antibody pembrolizumab (Keytruda) and the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab. Separate phase I studies of each drug...

Bladder Cancer
Prostate Cancer
Gynecologic Cancers

Clinical Trials Actively Recruiting Patients With Genitourinary Cancers

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with genitourinary cancers—prostate, bladder, uterine, and testicular. The trials are investigating genetic biomarkers of cancer; proton beam therapy; allogeneic bone marrow...

Solid Tumors
Bladder Cancer
Skin Cancer

PD-1/PD-L1 Inhibitors Show Promise in Additional Tumor Types

While inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1) are becoming established in melanoma, non–small cell lung cancer, and renal cell carcinoma, their efficacy is also being evaluated in numerous other tumor types, with promising results, according to studies presented...

bladder cancer

Study Finds Investigational Personalized Peptide Vaccination Increased Survival in Patients With Advanced Bladder Cancer

Although urothelial cancer of the bladder is sensitive to platinum-based chemotherapy, the vast majority of patients treated with these therapies will develop progressive disease within 8 months of treatment, and the median survival is reported to be between 13 and 15 months, according to a new...

bladder cancer

ECC 2015: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: Results of the IMvigor 210 Study

At the 2015 European Cancer Congress in Vienna, Austria, early results were announced (Abstract 21LBA) from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (anti–PD-L1; MPDL3280A) in people with locally advanced or metastatic urothelial...

issues in oncology
solid tumors
bladder cancer
issues in oncology

Study Identifies Genetic Mutations That Predict Response to Chemotherapy in Bladder Cancer

Although cisplatin-based neoadjuvant chemotherapy before cystectomy is the standard of care for muscle-invasive bladder cancer, only between 25% and 50% of patients achieve a pathologic response. A study investigating biomarkers that can predict response to chemotherapy in patients with...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

bladder cancer
issues in oncology

Similar Long-Term Outcomes With Robotic vs Traditional Surgery in Patients With Bladder Cancer

In the largest multi-institutional study to date, patients diagnosed with bladder cancer and treated with robot-assisted surgery experienced similar results to those who underwent a traditional open operation, according to research led by scientists at Roswell Park Cancer Institute (RPCI). The ...

issues in oncology
breast cancer
head and neck cancer
gynecologic cancer
issues in oncology
bladder cancer
issues in oncology

Immune Signaling Protein May Have Opposing Roles in Breast Cancer Development

Researchers at The University of Texas MD Anderson Cancer Center have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers, as research now shows TLR4 can either promote or inhibit breast cancer cell growth depending on mutations in...

solid tumors
bladder cancer

Adjuvant Chemotherapy Improves Survival in Patients With Locally Advanced Bladder Cancer

Patients who received chemotherapy after bladder cancer surgery demonstrated an approximately 30% lower risk of death than those who underwent surgery alone, according to an analysis presented by researchers at the Icahn School of Medicine at Mount Sinai at the 2015 Genitourinary Cancers Symposium, ...

bladder cancer

Laparoscopic Surgery for Bladder Cancer Leads to Good Long-Term Cancer Control

Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery,...

solid tumors
bladder cancer

No Overall Survival Difference for Immediate vs Deferred Chemotherapy After Radical Cystectomy in Muscle-Invasive Bladder Cancer

In the phase III EORTC 30994 trial reported in The Lancet Oncology, Sternberg et al found no overall survival difference between immediate and delayed adjuvant chemotherapy after radical cystectomy in patients with muscle-invasive urothelial carcinoma of the bladder. Immediate treatment was...

bladder cancer

Anti-PD-L1 Antibody Shows Activity in Metastatic Urothelial Bladder Cancer

As reported in a letter to Nature by Powles et al, the anti–PD ligand-1 (PD-L1) antibody MPDL3280A has shown good activity in patients with metastatic urothelial bladder cancer in a phase I study. Outcomes were best in patients with PD-L1 immunohistochemistry (IHC) expression of 2 or 3 in...

bladder cancer

‘Wound Response’ of Cancer Stem Cells May Explain Chemoresistance in Bladder Cancer

A novel mechanism—similar to how normal tissue stem cells respond to wounding—might explain why bladder cancer stem cells actively contribute to chemoresistance after multiple cycles of chemotherapy drug treatment. Targeting this “wound response” of cancer stem cells can...

solid tumors
bladder cancer

Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer

As reported in the Journal of the National Cancer Institute, Mitra et al have identified a novel genomic-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer. Use of the signature could help guide selection of patients for adjuvant therapy...

solid tumors
bladder cancer

RTOG Pooled Analysis Shows Good Long-Term Outcomes After Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer

In a pooled analysis of prospective Radiation Therapy Oncology Group (RTOG) studies reported in the Journal of Clinical Oncology, Mak et al found good long-term outcomes with bladder-preserving combined-modality therapy for muscle-invasive bladder cancer. Study Details The analysis included 468...

gynecologic cancer
colorectal cancer
head and neck cancer
kidney cancer
lung cancer
issues in oncology
bladder cancer
issues in oncology

14 Million Major Medical Conditions Attributable to Cigarette Smoking

At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...

bladder cancer

Increased Risk of Fracture After Radical Cystectomy and Urinary Diversion in Older Patients With Bladder Cancer

In a population-based study reported in the Journal of Clinical Oncology, Gupta et al found that radical cystectomy with urinary diversion for bladder cancer is associated with increased risk of bone fracture at any site in Medicare patients. Radical cystectomy and urinary diversion may cause...

bladder cancer

No Difference in Complication Rates or Hospital Stay With Robot-Assisted vs Open-Surgery Cystectomy in Bladder Cancer

In a trial reported in The New England Journal of Medicine, Bochner et al found no difference in complication rates or length of hospital stay with robot-assisted laparoscopic radical cystectomy vs open surgery in patients with bladder cancer. Blood loss was greater and procedure time shorter with...

bladder cancer

ASCO 2014: Investigational Anti–PD-L1 Antibody Demonstrates Promising Activity in Certain Patients With Metastatic Bladder Cancer

In a phase I study, the investigational anti–programmed death-ligand 1 (PD-L1) monoclonal antibody MPDL3280A demonstrated promising overall response rates in patients with previously treated metastatic urothelial bladder cancer whose tumors were characterized as PD-L1–positive. The ...

solid tumors
bladder cancer

Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim Is Effective, Well-Tolerated Neoadjuvant Therapy for Bladder Cancer

Although neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer, it is not widely used due to concerns over toxicity and delayed cystectomy. In a phase II trial reported in the Journal of Clinical Oncology, Plimack et al evaluated whether a neoadjuvant...

solid tumors
bladder cancer

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim: Safe and Effective in Muscle-Invasive Urothelial Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that a neoadjuvant four-cycle/8-week regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and effective in patients with muscle-invasive urothelial cancer. Study Details ...

bladder cancer

Perioperative Chemotherapy for High-Risk Bladder Cancer Improves Survival but Is Not Routinely Administered

A recent study published in Cancer found that, contrary to treatment guidelines for high-risk bladder cancer, neoadjuvant chemotherapy is not commonly used in routine clinical practice. Utilization of adjuvant chemotherapy was found to be increasing over time and was associated with a substantial...

issues in oncology
bladder cancer
issues in oncology

Certain Genetic Variants May Help Identify Patients at Increased Risk of Bladder Cancer Recurrence

A new study by Andrew et al published in BJU International suggests that certain inherited DNA sequences may affect the prognosis of patients with bladder cancer. The findings may help physicians identify subgroups of patients with high-risk bladder cancer who should receive more frequent...

issues in oncology
bladder cancer

DNA Test Can Help Predict Bladder Cancer Recurrence

A DNA methylation marker test performed on patients with noninvasive urothelial carcinoma can predict tumor recurrence with high sensitivity and specificity, according to a study by Su et al. The findings may help eliminate costly and unnecessary invasive exams and reveals the importance of DNA...

bladder cancer
issues in oncology

Patient With Bladder Cancer Shows Exceptional Response to Everolimus/Pazopanib Combination

A phase I study by Wagle et al of a combination of everolimus and pazopanib in patients with advanced solid tumors has identified a patient with bladder cancer who had a 14-month complete response. The patient had two concurrent mutations in mTOR, the target of everolimus (Afinitor), which may have ...

issues in oncology
breast cancer
bladder cancer
issues in oncology

Molecular Features of Invasive Bladder Cancer Resemble Those of Breast Cancer

Using whole-genome mRNA-expression profiling, researchers have identified three molecular subtypes of muscle-invasive bladder cancers that shared molecular features with basal and luminal breast cancers. The findings have important implications for prognostication, the future clinical development...

solid tumors
bladder cancer

Patients With Near-Complete Response After Induction Therapy May Be Candidates for Bladder-Sparing Therapy

Bladder-sparing approaches are typically reserved for patients with bladder cancer who have a complete response to combined modality induction therapy (radiation plus chemotherapy). A new phase II study suggests that patients with near-complete response should also be considered for bladder-sparing ...

solid tumors
bladder cancer
issues in oncology

Bladder Cancer Study Uncovers Potential Drug Targets and Molecular Similarities to Other Cancers

Investigators with The Cancer Genome Atlas Research Network have identified new potential therapeutic targets for urothelial carcinoma of the bladder, a common cancer that causes about 150,000 deaths worldwide each year. The researchers also found molecular similarities to some subtypes of breast,...

bladder cancer
issues in oncology

STAG2 Mutation Found Linked to Low-Risk Bladder Cancer

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. The findings, published in Nature Genetics, identified STAG2 as one of the most commonly mutated genes in bladder cancer,...

solid tumors
bladder cancer

Standard and Reduced High-Dose Volume Radiation Therapy for Muscle-Invasive Bladder Cancer Have Comparable Tumor Control

Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide comparable tumor control and decreased late toxicity when compared to surgery, according to a study published in the October issue of the International Journal of Radiation Oncology...

solid tumors
bladder cancer

Patients With Poor Nutritional Status Before Radical Cystectomy Have a Higher Risk of Postoperative Complications

Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented at the 2013 Clinical Congress of the American College of Surgeons....

solid tumors
bladder cancer

Bladder-sparing Trimodal Chemotherapy Produces Good Response in Patients with Muscle-invasive Bladder Cancer

In a phase II study reported in Lancet Oncology, Timur Mitin, MD, of Massachusetts General Hospital, and colleagues assessed the effects of adding paclitaxel or fluorouracil (5-FU) to radiation therapy plus cisplatin followed by adjuvant chemotherapy in a program of selected bladder preservation in ...

issues in oncology
solid tumors
bladder cancer

Bladder Cancer Could Recur despite Bladder Removal

Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests. The 5-year international study led by researchers at UT Southwestern validates the use of a marker...

Advertisement

Advertisement

;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.